This trial is testing a combination of two drugs to treat cancer patients with COVID-19 infection. The drugs are designed to stimulate the immune system to limit the replication and spread of the virus.
- Symptomatic COVID-19 Infection
- Blood Cancer
1 Primary · 3 Secondary · Reporting Duration: Up to 30 days post treatment intiation
Side Effects for
Awards & Highlights
3 Treatment Groups
Arm II/IV (standard of care)
1 of 3
Arm I (rintatolimod, recombinant interferon alfa-2b)
1 of 3
Arm III (rintatolimod)
1 of 3
64 Total Participants · 3 Treatment Groups
Primary Treatment: Recombinant Interferon Alfa-2b · No Placebo Group · Phase 1 & 2
Who is running the clinical trial?
Age 18+ · All Participants · 5 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
Frequently Asked Questions
What are the main indications for Recombinant Interferon Alfa-2b?
"Interferon Alfa-2b, which is created through genetic engineering, can be used to treat kaposi sarcoma. In addition, this medication can also alleviate symptoms for patients suffering from anthracycline-based chemotherapy, lymphadenopathy, and melanoma." - Anonymous Online Contributor
Are recruitment efforts for this trial still ongoing?
"The clinicaltrials.gov website verifies that this study, which was initially published on November 17th 2020, is still recruiting patients. In total, the trial needs 64 individuals from a single location." - Anonymous Online Contributor
Are there other ongoing research projects that use Recombinant Interferon Alfa-2b?
"32 total studies are currently underway for recombinant interferon alfa-2b, 10 of which are in phase 3. Although many trials for this treatment are based in Buffalo, New York, there are 3428 locations running studies globally." - Anonymous Online Contributor